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ABSTRACT

ARTICLE HISTORY

Genetic mutations lead to the production of mutated proteins from which peptides are presented to
T cells as cancer neoantigens. Evidence suggests that T cells that target neoantigens are the main
mediators of effective cancer immunotherapies. Although algorithms have been used to predict neoanti
gens, only a minority are immunogenic. The factors that influence neoantigen immunogenicity are not
completely understood. Here, we classified human neoantigen/neopeptide data into three categories
based on their TCR-pMHC binding events. We observed a conservative mutant orientation of the anchor
residue from immunogenic neoantigens which we termed the “NP” rule. By integrating this rule with an
existing prediction algorithm, we found improved performance in neoantigen prioritization. To better
understand this rule, we solved several neoantigen/MHC structures. These structures showed that
neoantigens that follow this rule not only increase peptide-MHC binding affinity but also create new TCRbinding features. These molecular insights highlight the value of immune-based classification in neoanti
gen studies and may enable the design of more effective cancer immunotherapies.
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Introduction
The immune system can recognize and destroy cancer cells1
and CD8+ T cells are a major component in this process.2–5
The recognition of tumor cells by CD8 + T cells requires at
least two components: expression of major histocompatibility
complex class I proteins (MHCI) on the cancer cells and
tumor-derived antigenic peptides which bind to MHCs.
T-cell receptors (TCRs) expressed by T cells recognize these
peptide-MHC complexes (pMHC) on cancer cells and target
them for destruction.
During the last 25 years, great effort has been made to
identify the tumor antigens that are targeted by T cells.6
Cancer antigens can be classified into two broad categories,
self-antigens which are expressed by some normal tissues but
are usually expressed at much higher levels by cancer cells (e.g.,
MART-1, HER2, CEA) and nonself-antigens, which include
antigens derived from oncogenic viruses (e.g., human papillo
mavirus), or neoantigens derived from somatic mutations in
cancer cells.7 Neoantigens are not present in normal tissues,
hence the immune system is not tolerant to them and views
them as foreign antigens.8,9 The targeting of neoantigens is
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ideal because they are not expressed by normal tissue and
therefore should not result in “on-target, off-tumor” toxicity
which can be observed in immunotherapies that target selfantigens. Moreover, unlike self-antigens, neoantigens are for
eign to the immune system and thus highly restricted TCRs
should exist in patients (i.e., not deleted during thymic
selection).
Currently, the identification of neoantigen relies on nextgeneration sequencing (NGS) to identify nonsynonymous
mutations, followed by predicting the theoretical binding of
the corresponding mutated peptides to the patient’s HLA
molecule10–16using peptide/MHCI binding prediction algo
rithms. Binding predictions have been used to narrow down
and select neoantigen candidates for use in immunotherapy
approaches as well as to help identify the minimal epitope
recognized by T cells.7,11,12,14,17–25 However, among the neo
peptides with predicted MHC binding, only a small portion of
them are immunogenic and therapeutically relevant.26,27 Other
parameters beyond peptide-MHC binding affinity could affect
neoantigen immunogenicity.
It has been hypothesized that TCR:pMHC ternary binding
events may influence neoantigen immunogenicity. Yadav et al.

CONTACT Lei Yin
yinlei@whu.edu.cn; Peng Bai
baipeng@whu.edu.cn
State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College
of Life Sciences, Wuhan University, Wuhan, China.
Supplemental data for this article can be accessed on the publisher’s website.
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

e1868130-2

P. BAI ET AL.

and Fritsch et al. suggested that the side chains of neoantigen
mutations pointing toward the TCR would be more immuno
genic while Duan et al. suggested that neoantigen substitutions
at MHC anchor positions may be more important.7,18,28
Recently, Capietto et al. also suggested that the increased
neoantigen-MHC affinity relative to the corresponding wildtype peptide is predictive of immunogenicity.29 However, stu
dies in this area are still limited due to the lack of large human
neoantigen datasets and neoantigen-MHC crystal structures.
Thus, systematic analyses based on human neoantigen data
and a structural understanding of neoantigen immune proper
ties are still needed.
Here, we attempted to determine immune features based on
validated neoantigens after mutation positional classification.
We found that almost all immunogenic anchor mutated
neoantigens in our datasets followed a conservative mutation
orientation (termed the NP rule), rather than other orienta
tions. Combining this rule with the binding predictor
NetMHCpan 4.024 could improve the performance of neoanti
gen prioritization. To provide structural insights of this rule,
we solved several pMHC structures: the KRAS G12D neoanti
gens in complex with HLA-C*08:02 and the ineffective mouse
DPAGT1 peptides in complex with a mouse MHC (H-2 Kb).
We showed that neoantigens that follow the NP rule could
generate immune features for T cell recognition. Our data also
suggest that the antigen exposed surface area may be associated
with neoantigen immunogenicity.

Materials and methods
Generation of the ineffective neopeptides dataset (IEND)
To generate a length-fitted ineffective neopeptide dataset,
mutant peptides from RIEND (Raw InEffective Neopeptides
Dataset) were cleaved into 9 mer and 10 mer containing muta
tions in silico and performed binding prediction with the
NetMHCpan 4.0 server.24 This newly generated dataset was
called the InEffective Neopeptide Dataset (IEND).
The mutant peptides (9 mer and 10 mer) were inputted in
the NetMHCpan 4.0 Server with custom python scripts. The
prediction of immunogenic neoantigens relies on
a recommend cutoff (IC50 < 500 nM) of a predicted MHCI
binding affinity.

Comparison of amino acid biochemical properties
Amino acid dissimilarity comparison of wild-type and mutant
amino acids was taken for peptide pairs between immunogenic
and ineffective cohorts based on the BLOSUM50 matrix.30 This
matrix provided BLOSUM scores represented the similarity of
amino acid pairs (higher score indicates more similar). Tails of
the violins to the range of the data were not trimmed. The
figure was generated by R. Statistical analyses were calculated
by Wilcoxon test.
The comparisons of “hydrophobicity”, “polarity”, and “side
chain bulkiness” scores of mutant amino acids between immu
nogenic and ineffective cohorts were taken based on indepen
dent numeric scales.31 Independent numeric scales of each
property were recorded in Supplementary Tables 1, 3, and 4.

Related figures were generated by R. Statistical analyses for the
“hydrophobicity”, “polarity”, and “side chain bulkiness” differ
ences were performed using Wilcoxon test.

Differential agretopic index (DAI) score calculation
The calculation of DAI was described previously.32 Briefly,
peptide binding affinity with HLAs was predicted by
NetMHCpan 4.0. The DAI score of each neoantigen pair was
calculated by subtraction of the neoantigen predicted IC50
binding affinity from the corresponding wild-type
counterparts.

Anchor, MHC-contacting, and TCR-contacting
positions determination
Anchors were defined for each allele based on the SYFPEITHI
database33 and the highest information content in the
NetMHCpan binding motif record.24 The anchor position for
each entry was cross-validated based on solved HLA structures
from Protein Data Bank (PDB). We recorded these results as
“consensus anchor” in IND and IEND (Supplementary Tables 1
and 3).
Peptide MHC-contacting and TCR-contacting positions
were determined based on solved peptide-MHC complex struc
tures. Briefly, the positions of peptides that were proved to be
non-anchor positions can be divided into MHC-contacting and
TCR-contacting positions. Based on pMHC structural models
from PDB, those positions which contact MHC were treated as
MHC-contacting positions. On the contrary, TCR-contacting
positions often harbor residues with side chains that point
toward outside from the pMHC complex and may contact
with TCRs. The MHC-contacting and TCR-contacting informa
tion of different HLAs was recorded in IND and IEND.

Antigen library and the determination of HLA anchor
position preference
The nonameric peptide libraries of 30 HLA alleles were
obtained from the IEDB database.34 Sequence logos were gen
erated using the sequence logo generator.35 The threshold for
preferential amino acids at anchor positions was set to include
and above 10% based on the nonameric peptide libraries from
IEDB. Related information was recorded in Supplementary
Tables 1 and 3.

Combined NP+binding (con NP+B) model building
To combine the NP rule with NetMHCpan 4.0, we used
a logistic regression algorithm. Analyses were performed
using the R “glm„ function, as below:
immunogenicity ~ NP + Binding prediction.
Anchor mutated neoantigen data were selected to train the
model. The performance of this model was shown by the ROC
curve.
The ROC curve was plotted from the false positive rate
(FPR) and true positive rate (TPR) values calculated by varying
the cutoff value (separating the predicted positive from the
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predicted negative) from high to low. The plots were generated
in R using the packages ggplot2 and plotROC.
To further test this model, we resampled 50 times. Random
resampling of the data (two-thirds resampling) was used for
training. The AUC values were calculated by plotROC package.
After iteration, the differences of AUC between the four mod
els were measured using paired t-test in R.

Protein expression, refolding, and purification
Inclusion bodies of HLA heavy chains and β2 M were
expressed as described previously.36 Briefly, The DNA encod
ing MHC heavy chain (HLA-C*08:02 and H-2 Kb) and light
chain (human β2 M and mouse β2 M) was synthesized (Idobio)
and cloned into pET-22(b) vector (Novagen). The vectors were
transformed into the E. coli strain BL21 DE3 (Novagen).
Transformants were selected on Luria broth (LB) agar plates
containing ampicillin. A single colony was selected and cul
tured in LB fluid medium with the antibiotics listed above at
37°C. Upon reaching an optical density OD600 of 0.6, expres
sion was induced with the addition of 1 mM IPTG. Incubation
continued at 37°C for 5 h. The cells were harvested by centri
fugation and then resuspended in PBS buffer with 1 mM PMSF
at 4°C. The cells were lysed, and the lysate was clarified by
centrifugation at 10,000 g to collect inclusion bodies. Inclusion
bodies were harvested and solubilized in 20 mM Tris (Vetec)
pH 8.0, 8 M urea (Vetec), 1 mM EDTA (BBI life sciences),
1 mM DTT (Sinopharm chemical reagent) and 0.2 mM PMSF
(Sinopharm chemical reagent).
Refolding was performed in the presence of MHC heavy
chain, β2M, and peptides as described previously.37 Briefly, the
resolubilized heavy chain (60 mg each) and the light chain
(25 mg each) in the presence of the corresponding peptide
were added into 1 liter of refolding buffer [100 mM Tris (pH
8.4), 0.5 mM oxidized glutathione (BBI life sciences), 5 mM
reduced glutathione (BBI life sciences), 400 mM L-arginine
(Vetec), 2 mM EDTA (BBI life sciences)]. After 48 h of refold
ing, the 1 L mixture was transferred into dialysis bags (Spectra)
and dialyzed against 15 liters of 10 mM Tris buffer (pH 8.0) at
4°C for 24 h.
Refolded proteins were purified by anion exchange chroma
tography with Q Sepharose HP (GE Healthcare) column then
Mono Q column (GE Healthcare) and concentrated by tangen
tial flow filtration using Amicon Ultra centrifugal filters
(Merck). For desalination and purification, samples were
loaded onto a Superdex 200 increase 10/300 GL column (GE
Healthcare)
for
size
exclusion
chromatography.
Chromatography was taken with BioLogic DuoFlow system
(Bio-rad) at a flow rate of 1 mL/min. Peak analysis was per
formed using the ASTRA software package (BioLogic
Chromatography Systems).

Thermal stability assay
The thermal stability assay was performed in the Real Time
Detection system (Roche). Each pMHC complex was diluted in
10 mM Tris-HCl (pH 8.0), 0.1 M NaCl buffer. The experiment
was performed in triplicates for different pMHC complexes.
Both pMHC complexes were heated from 10°C to 95°C with
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a heating rate of 1°C per minute. The fluorescence intensity
was measured with excitation at 530 nm and emission at 555
nm. The Tm represents the temperature for which 50% of the
protein is unfolded.

Crystallization, data collection, and processing
Purified pMHC complexes were concentrated to 10 mg/ml for
crystallization trials before screening using a series of kits from
Hampton Research. Protein complexes were crystallized by
sitting drop vapor diffusion technique at 4°C. Single crystals
of C08-mut9m and C08-mut10m were obtained in the condi
tion of 0.2 M ammonium acetate, 0.1 M HEPES (pH 6.5), 25%
w/v polyethylene glycol 3,350. For the H-2 Kb complex, single
crystals of Kb-8 mV and Kb-8 mL complex were obtained
when 4% v/v Tacsimate (pH 6.0), 12% w/v Polyethylene glycol
3,350 was used as the reservoir buffer.
Crystals were transferred to crystallization buffer containing
20% (w/v) glycerol and flash-cooled in liquid nitrogen imme
diately. The diffraction data were collected at the Shanghai
Synchrotron Radiation Facility (Shanghai, China) on beamline
BL17U1/BL18U1/BL19U1, and processed using the iMosflm
program.38 Data reduction was performed with Aimless and
Pointless in the CCP4 software suite.39 All structures were
determined by molecular replacement using Phaser.40 The
models from the molecular replacement were built using the
COOT (Crystallographic Object-Oriented Toolkit) program41
and subsequently subjected to refinement using Phenix
software.42 Data collection, processing, and refinement statis
tics are summarized in Supplementary Table 7. All the struc
tural figures were prepared using PyMOL (http://www.pymol.
org) program. The atomic coordinates and structure factors for
the reported crystal structures have been deposited on the
Protein Data Bank (PDB; http://www.rcsb.org/pdb/).

Results
Classification of cancer neoantigen/neopeptide data by
mutation position
We obtained MHCI-related, immunogenic (positive data,
termed neoantigen) and ineffective (negative data, termed
neopeptide) clinical human cancer neoantigen/neopeptide
data from a public database called NEPdb (http://nep.whu.
edu.cn). Herein, the mutant peptides which proved to induce
T cell response or led to clinical response in the context of
certain HLA are termed ‘neoantigen’. The mutant peptides
which did not induce T cell or clinical response are termed
‘neopeptide’. The neoantigen-HLA complex is termed ‘neoe
pitope’. These data were curated from 34 published studies that
contain neoantigen/neopeptide sequences and relevant HLAs.
All of the data were tested in in vitro T cell assays or clinical
therapies.5,12–14,43,11,21,44–54,17,19,55–62,22,63–65
The Immunogenic Neoantigen Dataset (IND) in this study
contains 128 neoantigens with corresponding MHCIs (Figure.
1a; Supplementary Table 1). The Raw InEffective Neopeptide
Dataset (RIEND) contains 11739 neopeptides with corre
sponding MHCIs (Figure. 1a; Supplementary Table 2). All of
these mutant peptides had been proven to be ineffective. The
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a
Immunogenic Neoantigen
Dataset
(IND)
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Neopeptide Dataset
(RIEND)
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N
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b
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1
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f
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Com NP+B
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0
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0.25
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1

Figure 1. Immune-based classification of data from the Immunogenic neoantigen dataset (IND) and Ineffective neopeptides dataset (IEND). a, Overview of the IND, RIEND, and IEND
datasets. b, Donut plots of the percentage of 9mer neoantigen/neopeptides, categorized into three classes based on different mutation positions: anchor mutation, MHC-contacting
position, and TCR-contacting position (immunogenic data, n =51; ineffective data, n=763). c, Nonameric peptides mutation distribution of three classes (mutated at anchor mutation,
MHC-contacting position, and TCR-contacting position) from IND and IEND. The frequency of mutation distribution at TCR-contacting position and MHC-contacting position showed
significant difference (TCR-contacting position, p=0.0378; MHC-contacting position, P=0.0027. n (immunogenic) =51; n (ineffective) =763. Fisher’s exact test). The percentage of
mutation distribution at the anchor position did not show a significant difference between immunogenic and ineffective data (ns, non-significant). d, Nonameric peptides distribution
of four subgroups (NN, NP, PN, and PP). A significant difference was observed in the NP group (p=8.247e-06, n=27 (immunogenic); n=425 (ineffective), Fisher’s exact test). e, Pie charts
represented the percentage of the NP group and non-NP groups in IND and IEND (n (immunogenic) = 27; n (ineffective) =425). f, Receiver operator characteristic (ROC) curve showed
the performance of four prediction models (DAI score, binary NP rule, binding prediction (Rank% scored by NetMHCpan 4.0), combination of NP rule + binding prediction (Com NP
+B)) with anchor mutated data (data from IND and IEND, n (immunogenic) = 27; n (ineffective) =425). The AUC (Area Under the ROC Curve) was calculated for each predictive model
(AUCDAI= 0.632; AUCNP rule =0.701; AUCcom NP-B =0.810; AUC Rank%=0.698).
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majority of them are not in the MHCI-fitted lengths (most
MHCI binders are 8–11 amino acids in length). To obtain
negative control for further study, we processed these raw
ineffective neopeptides into optimal MHC-binding length
(9 mer and 10 mer) in silico and used the NetMHCpan 4.0
algorithm for peptide-MHC binding prediction. This pro
cessed dataset is termed the InEffective Neopeptide Dataset
(IEND) and contains 2883 entries (Figure. 1a; Supplementary
Table 3).
A stable pMHC complex is helpful for effective TCR recog
nition and may induce T cell responses. Thus, neoepitope
candidates can be prioritized through prediction algorithms
by eliminating the peptides with weak binding affinity to
MHCIs. While binding prediction algorithms have been suc
cessfully used for eliminating candidate neoantigens, the pre
diction of true positive neoantigens remains quite low.66
Features beyond MHC-binding affinity are therefore involved
in neoantigen immunogenicity. Recently, some studies found
that the TCR:pMHC ternary binding events may influence
immunogenicity.67,68 However, the underlying immunological
mechanisms of how the binding events affect clinical outcome
in patients with cancer remain poorly defined.
To address the above questions, we classified peptides from
IND and IEND based on the mutation positions with different
functions during TCR:pMHC binding. Specifically, mutant
peptides from IND and IEND were categorized in the context
of MHCs into three categories, with mutations: 1) at anchor
positions that impact MHC binding; 2) at other MHCcontacting positions; and 3) that contact the TCR (i.e., point
toward TCRs instead of MHCs). The classification was per
formed by referencing the SYFPEITHI database,33 the
NetMHCpan antigen-binding motif viewer,24 and pMHC
structures from the Protein Data Bank database (PDB). The
classification information is shown in Supplementary Tables 1
and 3.
We next calculated the percentage of neoantigens in the
different categories. The immunogenic neoantigens were
more likely to mutate at TCR-contacting regions and less likely
to change at MHC-contacting regions as compared to those
ineffective neopeptides (Figure. 1 b, c), consistent with prior
reports.7,28 There was no difference in the frequency of neoan
tigen peptides that mutate at anchor positions in the immuno
genic neoantigens compared to the ineffective neopeptides
(Figure.1 c). This suggests that the classification of anchormutated peptides is not sufficient to distinguish the immuno
genic neoantigens from the ineffective candidates.
Next, we sought to identify amino acid biochemical proper
ties that define immunogenicity of neoantigens within the
category of the “TCR-contacting mutations”. We evaluated
four biochemical properties of amino acids, including “amino
acid dissimilarity”, “hydrophobicity”, “polarity”, and “side
chain bulkiness”, that discriminate between immunogenic
and ineffective cohorts. First, we defined dissimilarity of pep
tide pairs (the phrase “peptide pairs” refers to the mutant and
corresponding wild-type peptide), both for immunogenic and
ineffective data, by using normalized BLOSUM50 substitution
matrix.30 Next, “hydrophobicity”, “polarity”, and “side chain
bulkiness” properties were analyzed for mutations across
immunogenic and ineffective cohorts using independent
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numeric scales described by Chowell et al. (Supplementary
Table. 4).31 We found no significant difference for the four
properties between immunogenic and ineffective cohorts
(Supplementary Fig. 1). Thus, in our datasets, we found that
these four biochemical properties were not predictive for
neoantigen immunogenicity.

Anchor mutated neoantigens exhibit a conservative
mutation pattern to acquire immunogenicity
We aimed to further characterize intrinsic immunological
properties of anchor mutated neoantigens beyond binding
affinity. MHC molecules have many allelic variants with dif
ferent binding properties. Thus, the peptides recognized by
different MHCs are very diverse, with allele-specific amino
acid preferences. To investigate the preferential binding prop
erty of HLAs, we set the cutoff threshold above 10% as HLA
preferential amino acids at anchor positions as described
previously69,70 Specifically, we considered a call as preferential
amino acids only if the amino acids at a certain position yielded
at least a 10% enrichment, based on the binding-peptide
libraries from IEDB34 (Supplementary Fig. 2, Supplementary
Table 1 and 3). We classified the impact of a mutation at the
MHC anchor residues into the following four groups: 1) nonpreferential to non-preferential residues (NN); 2) nonpreferential to preferential residues (NP); 3) preferential to
non-preferential residues (PN); and 4) preferential to prefer
ential residues (PP) (Figure. 1d; Supplementary Table 5).
Statistical analysis showed a higher frequency of NP amino
acid mutations in the immunogenic dataset compared to
those in the ineffective dataset (Figure. 1d, p = 8.247e-06).
Interestingly, 26 in 27 (96%) of the immunogenic pairs can
be classified into the NP group. In contrast, peptide pairs in the
NN, PN, or PP groups were dramatically less immunogenic
(Figure. 1e; Supplementary Table 5).
Next, we further analyzed the 1/27 case in the immunogenic
cohort that did not follow the NP rule. This neoantigen
(MYADM R30W, derived from the MYADM protein) has
a mutation at the C-termini of the peptide.44 Notably, the
T-cell response was directed against both the wild-type and
mutant MYADM peptides which demonstrated that the wildtype MYADM peptide can bind to the patient’s HLA and elicit
an autoreactive T cell response in vivo. Neoantigens that elicit
T-cell responses that target the corresponding wild-type pep
tide may be less desirable to target due to the potential for
normal tissue targeting and tolerance. Overall, our observa
tions suggest that the NP rule is a conservative feature of
immunogenic anchor mutated neoantigens.
The NP rule of anchor mutated neoantigens thus can be
treated as a binary variable (1 = true NP, 0 = false NP). To
assess whether this variable can be used in neoantigen prior
itization, we respectively tested the performance of the binary
“NP” model, and the combination model of this binary model
with the NetMHCpan 4.0 Rank% model (termed Com NP+B).
Two prediction models, NetMHCpan 4.0 (using NetMHCpan
4.0 Rank% score) and the DAI models (differential agretopic
index, the difference of predicted binding affinity between the
mutated epitope and its unmutated counterpart) were also
tested with our data as benchmarks. After calculation, the
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“Com NP+B” model achieved better performance compared
with the other three models (Figure. 1 f, AUC = 0.810). When
comparing the performance of these four predictors, an assess
ment was also done by 50-fold cross-validation (two-thirds
random resampling) over the data to check whether the
observed difference in average AUC differs significantly
(Supplementary Fig. 3). Collectively, we proved that the NP
rule can be used as a predictive feature to improve neoantigen
prioritization.

Anchor mutated neoantigens can generate new
surface for T cell recognition
To understand how the NP rule forms the basis for under
standing the immunogenicity of anchor mutated neoantigens,
we attempted to solve structures of two neoepitopes containing
the KRAS G12D mutations in complex with HLA-C*08:02
(C08).12 Targeting of these neoepitopes with the adoptive
transfer of tumor-infiltrating lymphocytes (TIL) was associated
with an objective clinical response in a patient with metastatic
colorectal cancer. The TIL specifically recognized the KRAS
G12D 9 mer neoantigen GADGVGKSA and the 10 mer neoan
tigen GADGVGKSAL (both mutated at position 3 on the
peptides from glycine to aspartic acid), and not the wild-type
peptides, when presented by HLA-C*08:02. These two neoan
tigens can be categorized into the NP group (Supplementary
Table 1).
To investigate the properties of these neoepitopes, we
performed protein refolding for HLA-C*08:02 (C08) with
four peptides: the wild-type KRAS 9 mer GAGGVGKSA
(wt9m); the wild-type KRAS 10 mer peptide
GAGGVGKSAL (wt10m); the mutant KRAS G12D 9 mer
peptide GADGVGKSA (mut9m, mutation site is indicated
with underline), and the mutant KRAS G12D 10 mer peptide
GADGVGKSAL (mut10m). The C08-mut9m and C08mut10m complexes were successfully obtained by refolding
in vitro. However, the wt9m and wt10m peptides failed to
refold with HLA-C*08:02 even with a ten-fold increase in the
concentration of the peptides. To investigate binding details
of C08-mut9m and C08-mut10m complexes, we next per
formed thermal denaturation tests for C08-mut9m and C08mut10m respectively. Both pMHCs exhibited normal and
similar melting points (C08-mut9m, 50 ± 1.6°C; C08mut10m, 48 ± 1.1°C; Supplementary Table 6). These results
indicated that mut9m and the mut10m can stabilize the
pMHC complexes and exhibit similar stability after engaging
with HLA-C*08:02.
To identify potential structural differences of C08mut9m and C08-mut10m, we solved the crystal structures
of HLA-C*08:02 in complex with mut9m at 2.4 Å (PDB id:
6JTP) and mut10m at 1.9 Å (PDB id: 6JTN)
(Supplementary Table 7). Electron density for peptides
was unambiguous (Figure. 2a, b). C08-mut9m and C08mut10m showed conservative conformations except for
the peptide-regions (Figure. 2 c, d). Smaller residues such
as alanine and serine at peptide P1 and P2 positions are
preferably selected by HLA-C*08:02 (Figure. 2 e,
Supplementary Fig. 2) due to the narrow cleft formed by
several aromatic residues (Tyr7, Phe33, Tyr67, Tyr99,

Tyr59, Tyr171, Tyr159, and Trp167) which limited the
size of P1 and P2 (Figure. 2 f).
Generally, peptides use P2 and PΩ as anchor residues to
occupy the B and F pockets of MHCIs. However, the structures
of C08-mut9m and C08-mut10m revealed that mut9m and
mut10m used the unconventional P3 position as an anchor to
bind HLA-C*08:02 (Figure. 2 g, h). HLA-C*08:02 binds P3D
via the Arg97 and Arg156 residues. The side chain of P3D in
C08-mut9m also forms an intra-chain hydrogen bond with
P4G, while this bond is absent in C08-mut10m. Interestingly,
we found that the P3D anchor residue in C08-mut9m could
also provide TCR accessible surface by partially exposing its
charged side chain (Supplementary Fig. 4). This phenomenon
suggested that some neoantigens with anchor mutations can
not only increase pMHC binding force but also provide an
additional accessible surface for TCR interaction, under certain
conditions, and therefore affect the interactions with TCRs.
Although mut9m and mut10m occupied the same F pocket
with their PΩ residues, the P10L side chain from mut10m
buried deeper than P9A in C08-mut9m (Figure. 2g, h).
Meanwhile, instead of the TCR-oriented residue P8S on
mut9m, mut10m uses P8S as an auxiliary anchor to bind
HLAs via hydrogen bonds to Glu152 and Arg156. This residue,
together with P3D, squeezed the P4-P7 region of mut10m in
C08-mut10m (Figure. 2h). Together, the details of TCRbinding surfaces are largely different between C08-mut9m
and C08-mut10m. We postulated that these differences may
respectively modulate T cell recognition and activate different
T cell repertoires (discussed below). Meanwhile, structural
analysis of C08-mut9m and C08-mut10m suggested that
neoantigens with anchor mutations not only generate new
immune features but also create novel neoepitope surfaces. In
one sense, the newly generated neoepitope can be “seen” as
a totally foreign epitope by T cells. We postulated that the
anchor mutated neoantigens may be more immunogenic
than those neoantigens with non-anchor mutations.

Structure of a non-therapeutic neoantigen from
DPAGT1 in complex with mouse H-2 Kb
Yadav et al. described a neopeptide that can be presented by
a mouse MHC (H-2 Kb) but showed the ineffective property
in vivo.7 This mouse DPAGT1 V213L neopeptide contains
a mutated C-terminal anchor residue that falls into the “pre
ferential to preferential residues (PP)” group, with the chan
ging of valine (V) to leucine (L). We next solved the X-ray
crystal structures of these peptides in complex with H-2 Kb.
Soluble mouse H-2 Kb in complex with the mutant DPAGT1
V213L 8mer peptide (SIIVFNLL, termed mut8mL) and the
wild-type 8mer counterpart (SIIVFNLV, termed wt8mV)
were separately expressed, refolded, and purified for crystal
lization trials. Crystal diffraction data of Kb-wt8mV and Kbmut8mL were processed to 2.4 Å and 2.5 Å resolution respec
tively (Supplementary Table 7) and provided electron density
for each peptide (Figure. 3a).
The overall structure of Kb-wt8mV closely resembles that of
Kb-mut8mL except for a slight difference at PΩ (P8) (Figure.
3b). The PΩ residues acted as anchors in both Kb-wt8mV and
Kb-mut8mL (Figure. 3b). Moreover, both PΩ valine and
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Figure 2. Structural comparison of the C08-mut9m and C08-mut10m complexes. a-b, Unambiguous 2Fo-Fc electron density maps of the (a) KRAS G12D 9mer (GADGVGKSA, green)
and (b)10mer (GADGVGKSAL, yellow) neoantigens from the solved structures. The underlined amino acids represented the mutations. c, Overlay of the Cα traces (C08-mut9m, green;
C08-mut10m, yellow). d, Overlay of the mut9m (green) and mut10m (yellow) peptides. e, Polar interactions at peptide P1G and P2A positions. HLA-C*08:02 showed in grey. The
mut9m peptide showed in green and mut10m showed in yellow. f, Aromatic residues (green) from HLA-C*08:02, accommodating the P1 and P2 residues from peptides. g, The P3D
and P9A residues of mut9m peptide interact with HLA-C*08:02. h, The P3D, P8S, and P10LA residues of mut10m peptide interact with HLA-C*08:02.

leucine were preferably selected by H-2 Kb (Figure. 3 c). Both
of the two PΩ residues in these structures formed hydrogen
bonds with Asp77, Tyr84, Thr143, and Lys146 (Figure. 3d, e).
Although the side chain of leucine in mut8mL inserted deeper

into Kb than valine in wt8mV because of its longer side chain,
these two peptides did not provide a different TCR binding
surface with Kb (Figure. 3 b, d, e). These findings indicated that
the neopeptides with the “PP” rule cannot readily change

e1868130-8

P. BAI ET AL.

P6N

P6N

a

P4V

P4V
P7L

P3I

P1S

P1S

P8V

P5F

P2I

P7L

P3I

P2I

P5F

P8L

c
b
P6
P4

P7

Bits

P3

P1

P5

P8

P2

Positions

d

e
Asp77

Asp77

Tyr116

Tyr84

Tyr84

P8L

P8V

Thr143
Thr143

Lys146

Lys146

Figure 3. H-2 Kb presented DPAGT V213L wild-type peptide wt8mV and mutant peptide mut8mL in a similar manner a, Unambiguous 2Fo-Fc electron density maps of
the DPAGT1 wild-type 8mer peptide (wt8mV peptide SIIVFNLV, magenta) and mutant 8mer peptide (mut8mL peptide SIIVFNLL, orange) from solved structures. b,
Overlay of the wt8mV (magenta) and mutant mut8mL (orange) peptides. c, Sequence logo of H-2 Kb with 8mer peptides. The peptide library was obtained from IEDB
(n=4141). d, The anchor residue P8V of wt8mV interacts with H-2 Kb (grey). e, The anchor residue P8L of mut8mL interacts with H-2 Kb (grey).

binding surfaces and be immunogenic. Ineffectiveness of the
neopeptides with the PP rule might be explained by the pre
existence of the wild-type peptide-MHC complex in the thy
mus, which leads to negative selection of potential neopeptiderestricted T cell repertoires. Considering that peptide-MHC
binding is necessary for neoepitope immunogenicity, we do
not discuss the situations of the “PN” and “NN” rules.

Neoantigen exposed surface areas may affect T cell
selection in cancer immunotherapy
Peptide antigens can form stable complexes with HLAs by
lying within the HLA antigen-binding cleft. Some antigens,
called “featureless” antigens, have a relatively small exposed
surface area (ESA) from side chains pointing toward the
T cell receptor when they engage with HLAs.71 Studies have
indicated that featureless epitopes are more likely to select
relatively narrow TCR repertoires than epitopes with large

exposed features in vivo.72 We next examined the ESA
feature of C08-mut9m and C08-mut10m, by employing
the PDBePISA server. Of note, ESAs of two different
T cell epitopes were also calculated as benchmarks. One is
HLA-A2–M1, a viral antigen “M1” (M158-66 from the IAV)
in complex with HLA-A*02:01(A2-M1, in Figure. 4a),
which is considered a featureless epitope.73 In contrast,
the viral epitope HLA-A2-RT is a reverse transcriptase
peptide (RT468-476 from HIV) in complex with HLA-A*02
:01(called A2-RT, in Figure. 4a), and is considered as
a largely exposed epitope.74 After calculation, we found
that mut9m has the smallest ESA at 240 Å2 even less than
the well-known featureless M1 peptide (251 Å2 in Figure.
4a-c). However, mut10m has a relatively large ESA at 317
Å2 which is comparable to the typical largely exposed anti
gen RT (330 Å2 in Figure. 4a-c). These data suggested that
mut9m provides relatively less ESA than canonical T cell
antigens. We thus postulated that the diversity of C08-
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Figure 4. Different peptide exposed surface area (ESA) between C08-mut9m and C08-mut10m a, Peptide exposed surface area (ESA) of four pMHCs. ESA of A2-IAV M1
complex was calculated based on 2VLL (PDB ID). ESA of A2-HIV RT complex was calculated based on 2X4U. b, ESA of individual residues at each position of four peptides
within HLAs. c, Mut10m exhibits relatively large ESA compared to A2-IAV M1 (the featureless benchmark), C08-mut9m, and C08-mut10m. The HLA backbone surface
was shown in grey. IAV M1 (blue), mut9m (green), and mut10m (yellow) peptide surfaces were shown in different colors.d, Different T cell fates of KRAS G12D
neoantigen-restricted T cells reported by previous clinical studies. Rank in tumor sample represents the rank of restricted T cells in patient’s TILs before cell therapy. Rank
in infusion products represents the rank of restricted T cells in cell transfer products before cell transfer. Rank in blood represents the rank of restricted T cells in patients’
peripheral blood after cell transfer (d+ represents the day after cell transfer). The rank of T cells with the same TCR pair was validated in one or three different metastatic
tumor fragments from the patient. *, tested in three fragments; ND, not detected.

mut9m-restricted TCRs may be constrained in vivo because
of the featureless area available for TCR recognition.
Studies have suggested that only narrow TCR repertoires
can recognize featureless epitope, because of the lack of
TCR recognition modes.72,73,75 To observe the diversity of
KRAS G12D neoantigen-specific TCRs in clinical cases, we
examined the TCR sequences of those restricted T cell
repertoires targeting C08-mut9m (Figure. 4d, patients
3995 and 4095, both expressing HLA-C*08:02).12,57 Patient
3995 received ACT (adoptive cell transfer) treatments and
did not respond. In this trial, the transferred cell products
contain the RK5 (RK herein refers to ‘Restricted KRAS
G12D mutation’) T cell repertoire which can recognize
C08-mut9m. Patient 4095 received an ACT treatment and
observed objective tumor regressions. The RK1, RK3, RK4
T cell clones from this patient were verified to recognize

C08-mut9m while the RK2 clone recognized C08-mut10m.
All these four T cell clones (RK1, RK3, RK4, RK5) with
C08-mut9m restriction were identified to have biased usage
of a public TCR pair (TRAV4/TRBV5-1) across two
patients. The length and sequence of these TCRα chains
were highly restricted, with the same TCR-V region and the
“CLVGDxDQAGTALIF” CDR3α motif among the four
TCRs (Figure. 4d). TCRβ chains were also restricted at
TCR-V region but showed differences at CDR3β region.
Generally, the CDR1 and CDR2 loops of TCR can recog
nize the two conservative α-helixes on the MHC, whereas
the CDR3 loops mainly interact with the exposed peptide.
Moreover, CDR3β had proved to be the main factor that
determines TCR recognition (compared with CDR3α) in
many cases, due to greater sequence diversity and extensive
contacts to the peptide region.75 However, in this case, the
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C08-mut9m restricted TCR sequences of CDR1, CRR2, and
CDR3α were found to be consistent across different
patients. We thus speculated that these public regions of
CDR1, CDR2, and CDR3α are important in the C08mut9m recognition, rather than the CDR3β regions. In
contrast, the C08-mut10m neoepitope did not observe
dominant public TCRs in patient 4095 or across different
individuals. Collectively, these data suggested that the fea
tureless mut9m neoepitope can be recognized by T cells
with public and limited TCRs across different patients.
Previous reports have shown that constrained TCR repertoires
are associated with poor control of viral infection.76,77 However,
the correlation between TCR bias and clinical outcome in cancer
treatment is unclear. In an exploratory analysis, we examined the
TCR bias and clinical performance in the above cases. The C08mut9m restricted T cell clones with public TCR usage (RK1, RK3
RK4, and RK5) were not the top ranked clonotypes among the
TILs (Figure. 4d). However, the RK2 T cells with C08-mut10m
restriction showed dominant persistence in both TIL and the
blood after cell transfer. While we did not observe a direct corre
lation between TCR diversity and clinical outcome due to limita
tions in these clinical data, we still observed short-lived T cell
persistence in the presence of the featureless C08-mut9m neoe
pitope. We thus postulated that cancer patients who receive
neoantigen-based immunotherapies with characteristic (relatively
large ESA) neoantigens might obtain neoantigen-restricted T cells
with better persistence in vivo.

Discussion
How T cells recognize neoantigens as “non-self” is an impor
tant question in cancer immunotherapy. In contrast to con
ventional pathogenic peptides that are completely foreign,
neoantigens can differ from self by only a single amino acid.
Understanding the factors and mechanisms that contribute to
the immunogenicity of neoantigens may instruct the design of
future immunotherapies.
Efforts have been made to understand the complexity of
neoantigen immunogenicity with a major focus thus far on
peptide-MHC binding. Different studies have led to different
conclusions.78 Fritsch et al. and Yadav et al. suggest that
immunogenic neoantigens are more commonly mutated at
a TCR-contacting residue, while Duan et al. suggested that
neoantigen substitutions at MHC anchor residues may be
more immunogenic.7,18,28 Further, using mouse models,
Capietto et al. showed that increased affinity relative to the
corresponding wild-type peptide can influence neoantigen
immunogenicity.29 We found that mutations occur more fre
quently at TCR-contacting positions rather than MHCcontacting positions in the immunogenic dataset. However,
amino acid biochemical properties might not be critical for
neoantigen filtering for candidates with TCR-contacting posi
tion mutation. For mutations that occur at the MHC anchor
positions, we showed that the NP rule of anchor mutated
neoantigens exists pervasively. Also, we found that the NP
rule combines with the MHC-binding predictor NetMHCpan
4.0 to enhance the prioritization of neoantigen candidates. In
a sense, the NP feature could be captured by existing neoanti
gen predictors through the comparison of binding differences

between wild-type and mutant peptides.18,79,80 However, the
NP rule we provide here is a binary feature that can provide
a direct understanding of neoantigen immunogenicity.
Nevertheless, the robustness of the NP rule will need to be
tested with larger sample sizes.
We also performed structural studies to obtain insights
into the NP rule. We found that anchor mutated neoanti
gens that followed the NP rule can generate new surfaces
and features for T cell recognition that the wild-type pep
tide cannot. In contrast, the anchor mutated neopeptide
from DPAGT1 with PP rule exhibited low immunogenicity
in clinical treatment. It is possible that most of the neoe
pitope restricted T cells were also cross-reactive with wildtype and thus were removed by negative selection. Our data
also suggest that neoantigen exposed surface area (ESA)
might be a factor that influences TCR diversity and clinical
outcome, but more experimental data and neoantigen-MHC
structures are needed to fully understand the relevance
between ESA and TCR diversity.
Our study showed three possible neoantigen binding mod
els within the context of MHC (Supplementary Fig. 5). Model
A represents the situation in which a mutation occurs in the
peptide that contacts TCR. Model B represents the situation in
which a mutation occurs at a non-anchor MHC-contacting
region and therefore might be least immunogenic. Model
C represents the situation in which a mutation occurs at
MHC anchor position. Anchor mutations may not change
the TCR-contacting surface but instead lead to enhanced de
novo presentation of the peptide for TCR recognition.
KRAS G12D is one of the most common driver mutations
that leads to oncogenesis.81 It is also indicative of poor prog
nosis with poor response to standard cancer treatments. The
transfer of HLA-C*08:02-restricted T cells targeting KRAS
G12D neoantigens was associated with clinical response.
Based on these pMHC structures, further research could be
undertaken to increase the immunogenicity and stability of the
KRAS G12D-C*08:02 neoepitope, by making modifications of
agonist peptides or by screening non-natural synthetic
epitopes.82,83 Our structures could also be used to design arti
ficial receptors/proteins that bind mutant KRAS peptides based
on synthetic biology approaches.
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